Dr. med. Patrik Weder
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery J, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye A, Müller A, Membrez-Antonioli V, Gerard M, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2023
Aug 10, 2023Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Aug 10, 2023JAMA Oncol 2023
Huober Jens, Weder Patrik, Ribi Karin, Thürlimann Beat, Thery Jean-Christophe, Li Qiyu, Vanlemmens Laurence, Guiu Séverine, Brain Etienne, Grenier Julien, Dalenc Florence, Levy Christelle, Savoye Aude-Marie, Müller Andreas S, Membrez-Antonioli Véronique, Gerard Marie-Aline, Lemonnier Jérôme, Hawle Hanne, Dietrich Daniel, Boven Epie, Bonnefoi Hervé R, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC cancer 2019; 19:902.
Sep 10, 2019Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sep 10, 2019BMC cancer 2019; 19:902
Schmid Sabine, Zaman Khalil, Weder Patrik, von Moos Roger, Thürlimann Beat, Rochlitz Christoph, Pestalozzi Bernhard, Pagani Olivia, Oehlschlegel Christian, Nolè Franco, Munzone Elisabetta, Mamot Christoph, Goldhirsch Aron, Aebi Stefan, Klingbiel Dirk, Ruhstaller Thomas
Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocr Connect 2017; 6:549-556.
Aug 16, 2017Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients
Aug 16, 2017Endocr Connect 2017; 6:549-556
Zweifel Martin, Sessa Cristiana, Schoenfeld Wolfgang, Tapia Coya, Brauchli Peter, Hawle Hanne, Pilop Christiane, Rothgiesser Karin M, Bigler Martin, Pagani Olivia, von Moos Roger, Weder Patrik, Riniker Salome, Thürlimann Beat
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens C, Mateus C, Mohr P, Paetzold S, Satzger I, Schadendorf D, Schlaeppi M, Schuler G, Schuler-Thurner B, Trefzer U, Ulrich J, Vaubel J, von Moos R, Weder P, Wilhelm T, Göppner D, Dummer R, Klein C, Keller U, Goldinger S, Loquai C, Robert C, Kaehler K, Berking C, Bergmann T, Bockmeyer C, Eigentler T, Fluck M, Garbe C, Gutzmer R, Grabbe S, Hauschild A, Hein R, Hundorfean G, Justich A, Heinzerling L. The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PloS one 2013; 8:e53745.
Jan 14, 2013The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Jan 14, 2013PloS one 2013; 8:e53745
Voskens Caroline J, Mateus Christine, Mohr Peter, Paetzold Sylvie, Satzger Imke, Schadendorf Dirk, Schlaeppi Marc, Schuler Gerold, Schuler-Thurner Beatrice, Trefzer Uwe, Ulrich Jens, Vaubel Julia, von Moos Roger, Weder Patrik, Wilhelm Tabea, Göppner Daniela, Dummer Reinhard, Klein Christina, Keller Ullrich, Goldinger Simone M, Loquai Carmen, Robert Caroline, Kaehler Katharina C, Berking Carola, Bergmann Tanja, Bockmeyer Clemens L, Eigentler Thomas, Fluck Michael, Garbe Claus, Gutzmer Ralf, Grabbe Stephan, Hauschild Axel, Hein Rüdiger, Hundorfean Gheorghe, Justich Armin, Heinzerling Lucie M
Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
Hundsberger T, Brügge D, Putora P, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 2013; 112:133-9.
Jan 12, 2013Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas
Jan 12, 2013J Neurooncol 2013; 112:133-9
Hundsberger Thomas, Brügge Detlef, Putora Paul Martin, Weder Patrik, Weber Johannes, Plasswilm Ludwig
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50:630-5.
Apr 18, 2011Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Apr 18, 2011Acta Oncol 2011; 50:630-5
Hofer Silvia, Wick Wolfgang, Zander Thilo, Weder Patrik, Roelcke Ulrich, Pichler Josef, Ochsenbein Adrian, Marosi Christine, Lemke Dieter, Huber Urs, Hottinger Andreas F, Greil Richard, Elandt Katarzyna, Weller Michael
Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas
Brügge D, Putora P, Hundsberger T, Weder P, van Leyen K, Plasswilm L (2011). Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas.
Mar 31, 2011Re-Irradiation with Bevacizumab in Recurrent Malignant Gliomas
Mar 31, 2011SASRO 2011
Brügge Detlef, Putora Paul Martin, Hundsberger Thomas, Weder Patrik, van Leyen Karin, Plasswilm Ludwig
Neue Behandlungsoptionen beim metatstasierten Kolorektalkarzinom
Baumann M, Weder P, Köberle D. Neue Behandlungsoptionen beim metatstasierten Kolorektalkarzinom - Bewertung der aktuellen Studeienresultate und Konsequenzen. Schweizer Zeitschrift für Onkologie 2009:14-19.
Jan 1, 2009Neue Behandlungsoptionen beim metatstasierten Kolorektalkarzinom
Jan 1, 2009Schweizer Zeitschrift für Onkologie 2009:14-19
Baumann Michael, Weder Patrik, Köberle Dieter
Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab
Weder P, Anliker M, Itin P, Bargetzi M. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. Dermatology 2004:3-281.
Feb 16, 2004Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab
Feb 16, 2004Dermatology 2004:3-281
Weder Patrik, Anliker Mark, Itin P, Bargetzi M
Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab
Weder P, Anliker M, Itin P, Bargetzi M. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. Dermatology (Basel, Switzerland) 2004; 208:281-3.
Jan 1, 2004Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab
Jan 1, 2004Dermatology (Basel, Switzerland) 2004; 208:281-3
Weder Patrik, Anliker M, Itin P, Bargetzi M